idea-003 · investor messages

Every line ends in the claim that substantiates it and that claim's own confidence tag, or is marked unsubstantiated. A message set never upgrades a tag, invents a number, or states anything the candidate's intended use does not cover.

Commutable patient-matrix reference material panel for validating tumor-informed ctDNA MRD assays (clinical QC material) — investor messages

Intended use: Quality control material — intended for use by molecular laboratories to monitor the analytical performance (analytical sensitivity at defined low tumor fractions, specificity, and inter-run precision) of tumor-informed circulating tumor DNA minimal residual disease assays, during assay validation and in routine run-by-run quality control. Not a calibrator, and not for use in establishing or interpreting an individual patient result.

Messages

The problem: Every laboratory that brings up a tumor-informed MRD (molecular residual disease) test outside FDA (US Food and Drug Administration) review has to establish its analytical sensitivity before it reports a single patient result, and the regulation that requires it names no material, no source and no traceability for doing so. Each lab improvises its own. claim 76verified
Why now: Our customers' test is now a paid test. Medicare's CY2026 national limitation amount for 0340U is $3,590.00 per service, and Medicare fee-for-service alone recorded 25,746 of those services in 2024. That is the customer's revenue, not ours, and it is a floor on one payer, not a market size. claim 71verified claim 68verified
The volume behind it: The two largest MRD testing companies are reporting their fastest volume growth yet — Natera its largest sequential quarterly increase in clinical MRD units, Guardant Reveal volume more than doubling year over year. claim 43unconfirmed claim 44unconfirmed
Where incumbents stop: No commercial ctDNA (circulating tumour DNA) material we have found gives a laboratory a characterized level below 0.1% VAF (variant allele frequency) in human plasma. The one incumbent product that goes lower ships as purified DNA in buffer. claim 184unconfirmed
Why 0.1% is a real wall: In a nine-laboratory BLOODPAC study of commercially available contrived ctDNA materials, concordance and sensitivity were high above 0.1% VAF and fell at 0.1%. The field's own materials run out exactly where MRD assays start to operate. claim 94verified
What we measure and what we derive: An interlaboratory ddPCR study agreed with gravimetric values from 53.9% down to 0.1% VAF, with a limit of quantification of 0.1%. So we measure by digital PCR down to 0.1% and no lower, and every level beneath it says "derived by dilution" on the label. We do not claim to measure what the instrument cannot. claim 100verified
What we are selling: A multi-level validation panel in pooled human donor plasma, with a stated expanded uncertainty at every level, levels below 0.1% value-assigned by gravimetric dilution from a dPCR (digital polymerase chain reaction)-quantified parent into a dPCR-quantified diluent. claim 134unconfirmed
Where the money is: The recurring business is the daily-use control consumed on every run of patient testing, not the panel bought at validation. That line carries most of the serviceable pool. claim 151unconfirmed
Why the demand recurs: CLIA (Clinical Laboratory Improvement Amendments) requires every laboratory to have control procedures that monitor the accuracy and precision of the complete analytic process, for each test system. claim 7verified
The regulatory route: FDA lists product code SCU (subcutaneous), "DNA and RNA Oncology Controls", as a Class II (FDA device class II) device under 21 CFR (Title 21 of the Code of Federal Regulations) 866.5910 with a 510(k) (premarket notification)-exempt submission type. That is the code this product launches against. It is not a clearance and we will never call it an approval. claim 131verified
What the route costs before the first sale: SCU is not GMP-exempt. Launching under 866.5910 means an ISO (International Organization for Standardization) 13485 quality system with design controls, UDI (unique device identifier) and complaint reporting in place before first commercial distribution. That cost comes first, and it is known. claim 159verified
What the route still needs: That the 510(k) exemption applies to this material — rather than being withdrawn by the neoplastic-disease limitation in 866.9(c)(1) — is an FDA reading we have not obtained. If it goes the other way, a 510(k) comes before revenue. claim 52unconfirmed
What we are betting: That at least one in ten US laboratories running tumor-informed MRD tests on patients will move their run-by-run external control off in-house contrived material and onto a native-plasma control with its molecule count on the label. claim 177unconfirmed
Why us: The characterization dataset and the documented value-assignment chain are the product. A fast follower would have to match them, not just ship a vial. claim 128unconfirmed
The patents in the room: Three live US patents on cell-free DNA testing standards and cfDNA (cell-free DNA) reference-material generation run to 2034, 2036 and 2038 on naive term. We have their titles and dates, not a reading of their claims, and we say so. claim 102verified claim 103verified claim 104verified
What would prove us wrong: If the spiked fragments come out of extraction differently from the donor plasma's own cfDNA, this is a spiked control like every other one. That hazard is documented: a 15-site CANCER-ID study found some extraction kits preferentially recovered spiked DNA over endogenous plasma cfDNA. We have not yet shown ours avoids it. claim 92verified
The physics limit: At 10-30 ng of cfDNA input, 40%-74% of inputs at 0.01% VAF contain no mutant copy of any single variant. The lowest levels are Poisson-limited, which is why the daily control is set where a run reliably contains molecules, not at the lowest level we can dilute to. claim 133unconfirmed
What we cannot tell you yet: A unit cost. No bottom-up cost-of-goods build exists at any stated production volume, and under this route the business is fixed-cost at planning volumes, so the cost side is the side that decides it. claim 140unconfirmed

Beyond intended use

Any message above that asserts a population, setting, duration or outcome the intended use does not state. None. is a valid answer and the honest one for most candidates. An absent section is a failure.

None exceed it on population, setting, duration or outcome. Three edges were checked and are named so a reader can disagree:

The customers' patient test is described, never claimed for. Why now and **The volume behind it** describe the reimbursement and growth of the laboratories' own MRD tests. No message says or implies that this material changes a patient result, a recurrence finding or a clinical outcome; the intended use excludes establishing or interpreting an individual patient result, and the set keeps every clinical sentence on the customer's side of that line.
"Validation panel" sold to assay developers. The intended use names "molecular laboratories" as users "during assay validation". The business case also sells the panel to IVD (in vitro diagnostic) kit makers and pharma/CRO assay groups that report no patient results. No message here names those buyers, and whether "during assay validation" falls inside 866.5910(a)'s identification at all is itself open (claim 156unconfirmed) — so this set does not extend the user population past the intended use's wording.
Precision is claimed only where the counts support it. The intended use lists inter-run precision. The physics limit narrows, not widens, that: below a usable molecule count the lowest levels monitor detection only (the design condition is claim 161unconfirmed). Narrower than the label is not off-label.

What we cannot say yet

Every message above whose backing is not verified. The checker enforces set equality — exactly these lines, no more and no fewer.

The volume behind it: both growth figures come from an earnings release and a call transcript no connector reaches; neither has been independently checked — claim 43unconfirmed claim 44unconfirmed
Where incumbents stop: a negative across a whole catalogue space, written back today; Twist and AcroMetrix plasma material have not been read to the level, and the incumbent datasheets behind it are themselves unconfirmed — claim 184unconfirmed
What we are selling: no lot, no dilution chain and no uncertainty budget exists yet; the 35% (k=2) bar is a design condition on an unbuilt product — claim 134unconfirmed
Where the money is: a demand forecast built on a 250-vials-a-year leg that is a CLIA minimum read as a consumption rate — claim 151unconfirmed
What the route still needs: an FDA intended-use judgment that only a 513(g) response settles — claim 52unconfirmed
What we are betting: a switching and willingness-to-pay claim the adoption connector refuses by design; no laboratory has been asked — claim 177unconfirmed
Why us: a stakeholder-future claim; nothing establishes that buyers weigh the dataset at all — claim 128unconfirmed
The physics limit: the arithmetic is internally correct but its 10-30 ng input range and 3.3 pg constant are unverified inputs — claim 133unconfirmed
What we cannot tell you yet: the cost build-up does not exist — claim 140unconfirmed

Words on this page14 abbreviation(s) and code(s), with what each stands for — copied from _shared/plain-language.md

21 CFR: Title 21 of the Code of Federal Regulations — the US food-and-drug rulebook; a number after it is one regulation, often the one that classifies a device type
510(k): premarket notification — the FDA route for a device shown to be as safe and effective as one already on the market; months, no clinical trial as a rule
cfDNA: cell-free DNA — DNA fragments floating in the blood, most of them from normal cells
Class II: FDA device class II — moderate-risk devices, usually cleared by 510(k)
CLIA: Clinical Laboratory Improvement Amendments — the US rules a clinical laboratory must meet to report test results on patients
ctDNA: circulating tumour DNA — fragments of a tumour's DNA found in the blood
dPCR: digital polymerase chain reaction — a laboratory method that counts individual DNA molecules
FDA: US Food and Drug Administration — the US regulator that clears or approves a device before it can be sold
ISO: International Organization for Standardization — the body whose numbered standards devices and laboratories are tested against
IVD: in vitro diagnostic — a test run on a sample taken from the body rather than on the body
MRD: molecular residual disease — cancer left behind after treatment, too little to see on a scan, detected through DNA in the blood
SCU: subcutaneous — under the skin
UDI: unique device identifier — the barcode-style id every marketed device carries
VAF: variant allele frequency — what share of the DNA fragments at one position carry the tumour's mutation; the lower it is, the harder the test

Generated from knowledge-base/messaging/idea-003-investor.md by engine/scripts/build_review.py on 2026-10-04. This page is a view — edit the source file and rebuild, never edit here.